Back to Search
DANIEL FURST, MD
MD
Rheumatology Physician
NPI: 1821023599IndividualAccepts Medicare
Specialties, Licenses & Credentials
Rheumatology PhysicianPrimary
Internal Medicine — Rheumatology
Code: 207RR0500X
G26247(CA)
Education
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Class of 1968
Research & Publications (20)
The risk of infections with biologic therapies for rheumatoid arthritis.
PMID 19117595·Semin Arthritis Rheum·2010
6-review
Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA?
PMID 19190623·Nat Clin Pract Rheumatol·2009
8-other
Serum immunoglobulins and risk of infection: how low can you go?
PMID 18620738·Semin Arthritis Rheum·2009
6-review
High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease.
PMID 18641099·Chest·2008
2-rct
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
PMID 19022808·Ann Rheum Dis·2008
8-other
Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel.
PMID 18178593·Rheumatology (Oxford)·2008
4-observational
Outcome measures in rheumatologic clinical trials and systemic sclerosis.
PMID 18784136·Rheumatology (Oxford)·2008
8-other
Systemic sclerosis - continuing progress in developing clinical measures of response.
PMID 17477486·J Rheumatol·2007
4-observational
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
PMID 17934088·Ann Rheum Dis·2007
6-review
Measuring outcomes in PAH: the gap between the measures that are used and their validity.
PMID 17804569·Ann N Y Acad Sci·2007
8-other
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.
PMID 17412737·Ann Rheum Dis·2007
4-observational
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
PMID 17038465·Ann Rheum Dis·2006
8-other
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.
PMID 16884970·Semin Arthritis Rheum·2006
4-observational
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
PMID 16331754·J Rheumatol·2005
3-trial
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
PMID 16239380·Ann Rheum Dis·2005
6-review
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
PMID 15479866·Ann Rheum Dis·2004
6-review
Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
PMID 15823761·Clin Ther·2004
6-review
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
PMID 14532138·Ann Rheum Dis·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 575 E HARDY ST STE 321
INGLEWOOD, CA 90301 - Phone
- (818) 561-9989
Quick Facts
- NPI
- 1821023599
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 58
- Publications
- 20
Are you this provider?
Claim Your Profile